Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for nonmetastatic castration-resistant prostate cancer (nmCRPC).

Karim Fizazi, Neal D. Shore, Teuvo Tammela, Albertas Ulys, Egils Vjaters, Sergey Polyakov, Mindaugas Jievaltas, Murilo Luz, Boris Alekseev, Iris Kuss, Marie-Aude Le Berre, Oana Petrenciuc, Amir Snapir, Toni Sarapohja, Matthew Raymond Smith

Research output: Contribution to journal › Meeting Abstract › peer-review

Fingerprint

Dive into the research topics of 'Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for nonmetastatic castration-resistant prostate cancer (nmCRPC).'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science

Agricultural and Biological Sciences